[{"id":"77cb581e-c173-4f2c-a06e-c96db7736264","acronym":"RAS-HEMATO","url":"https://clinicaltrials.gov/study/NCT04286360","created_at":"2021-01-18T20:48:27.393Z","updated_at":"2024-07-02T16:34:59.177Z","phase":"","brief_title":"Hematological Anomalies in Children With Rasopathy","source_id_and_acronym":"NCT04286360 - RAS-HEMATO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1","pipe":" | ","alterations":" BRAF mutation • CBL mutation • MAP2K1 mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • CBL mutation • MAP2K1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/11/2020","start_date":" 11/11/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-06-04"},{"id":"0586b97f-ca3e-4935-90c4-ce0d935a32d9","acronym":"NCI-2020-05261","url":"https://clinicaltrials.gov/study/NCT04493138","created_at":"2021-01-18T21:35:02.627Z","updated_at":"2024-07-02T16:34:59.952Z","phase":"Phase 1/2","brief_title":"Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations","source_id_and_acronym":"NCT04493138 - NCI-2020-05261","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ASXL1","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation","tags":["TP53 • FLT3 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Vanflyta (quizartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-30"},{"id":"7228addd-99a0-4c5e-a6f3-befe14f6f6de","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800210","created_at":"2023-04-05T14:03:37.666Z","updated_at":"2024-07-02T16:35:05.164Z","phase":"Phase 2","brief_title":"Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases","source_id_and_acronym":"NCT05800210","lead_sponsor":"University of Florida","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • CBL mutation • Chr t(9;11)","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • CBL mutation • Chr t(9;11)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/03/2024","start_date":" 05/03/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-05-08"},{"id":"3b52b9d4-20d4-4a79-a816-f21eb9b91b3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807932","created_at":"2023-04-11T14:03:36.196Z","updated_at":"2024-07-02T16:35:06.548Z","phase":"Phase 1/2","brief_title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","source_id_and_acronym":"NCT05807932","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation","tags":["KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • fludarabine IV • Grafapex (treosulfan) • Amsidine (amsacrine)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/30/2028","study_completion_date":" 01/30/2028","last_update_posted":"2024-05-01"},{"id":"0f841029-f2ce-4cb1-849c-75709569b46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03613532","created_at":"2021-03-05T16:52:31.672Z","updated_at":"2024-07-02T16:35:22.047Z","phase":"Phase 1","brief_title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","source_id_and_acronym":"NCT03613532","lead_sponsor":"Jacqueline Garcia, MD","biomarkers":" KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type","tags":["KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-26"},{"id":"04cc697b-a936-4795-aed4-1231c763328e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441514","created_at":"2022-07-01T20:56:41.287Z","updated_at":"2024-07-02T16:35:25.985Z","phase":"Phase 1","brief_title":"Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05441514","lead_sponsor":"City of Hope Medical Center","biomarkers":" KRAS • BRAF • NRAS • IDH2 • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • IDH2 mutation • NF1 mutation • RAS mutation • CBL mutation • IDH2 R140 • IDH2 R172","tags":["KRAS • BRAF • NRAS • IDH2 • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • IDH2 mutation • NF1 mutation • RAS mutation • CBL mutation • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 05/02/2025","study_completion_date":" 05/02/2025","last_update_posted":"2023-12-18"},{"id":"a6aad9f1-0518-4d3b-a71b-32706868cb46","acronym":"ADVL1521","url":"https://clinicaltrials.gov/study/NCT03190915","created_at":"2021-01-18T15:44:00.418Z","updated_at":"2024-07-02T16:35:29.990Z","phase":"Phase 2","brief_title":"Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia","source_id_and_acronym":"NCT03190915 - ADVL1521","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1 • PTPN11","pipe":" | ","alterations":" NF1 mutation • RAS mutation • PTPN11 mutation • CBL mutation","tags":["NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation • RAS mutation • PTPN11 mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/09/2018","start_date":" 09/09/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-08"},{"id":"7de7e1ee-5af6-45a1-8fb5-cc69121b84de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04487106","created_at":"2021-01-18T21:32:24.763Z","updated_at":"2024-07-02T16:35:53.866Z","phase":"Phase 2","brief_title":"Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT04487106","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • NRAS • KIT • HRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KIT mutation • NF1 mutation • HRAS mutation • CBL mutation","tags":["KRAS • BRAF • NRAS • KIT • HRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KIT mutation • NF1 mutation • HRAS mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Mekinist (trametinib) • azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 02/09/2023","primary_completion_date":" 02/09/2023","study_txt":" Completion: 02/09/2023","study_completion_date":" 02/09/2023","last_update_posted":"2023-03-07"},{"id":"f0387d12-fa4e-40e1-addf-226e0d4ad5ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00900328","created_at":"2021-01-18T03:28:03.237Z","updated_at":"2024-07-02T16:37:19.075Z","phase":"","brief_title":"Study of Tumor Samples From Patients With Lung Cancer","source_id_and_acronym":"NCT00900328","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" EGFR • KRAS • ALK • TP53 • MET • CBL","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • EGFR mutation • EGFR expression • MET overexpression • MET expression • CBL mutation • ALK translocation • TP53 expression • KRAS expression","tags":["EGFR • KRAS • ALK • TP53 • MET • CBL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • EGFR mutation • EGFR expression • MET overexpression • MET expression • CBL mutation • ALK translocation • TP53 expression • KRAS expression"],"overall_status":"Completed","enrollment":" Enrollment 280","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":" Completion: 09/01/2012","study_completion_date":" 09/01/2012","last_update_posted":"2017-08-08"}]